Leap Therapeutics Inc Asset Resilience Ratio
Leap Therapeutics Inc asset resilience ratio. Leap Therapeutics Inc (LPTX) has an Asset Resilience Ratio of 10.59% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LPTX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Leap Therapeutics Inc (2014–2022)
Asset resilience ratio of Leap Therapeutics Inc from 2014 to 2022. This chart shows how Leap Therapeutics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Leap Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Leap Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LPTX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.87 Million | 10.59% |
| Total Liquid Assets | $40.87 Million | 10.59% |
Asset Resilience Insights
- Moderate Liquidity: Leap Therapeutics Inc has 10.59% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Leap Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Leap Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Leap Therapeutics Inc Asset Resilience Ratio by Year (2014–2022)
Leap Therapeutics Inc asset resilience ratio by year from 2014 to 2022. The table below shows the annual Asset Resilience Ratio data for Leap Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 39.19% | $22.76 Million | $58.09 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $29.06 Million | -- |
| 2015-12-31 | 23.47% | $6.61 Million | $28.15 Million | -49.04pp |
| 2014-12-31 | 72.51% | $35.31 Million | $48.70 Million | -- |
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more